Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 3Neoplasms 3Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemangioma 2Carcinoma, Non-Small-Cell Lung 2Radiation Pneumonitis 1Radiation Injuries 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Lung Diseases, Interstitial 1Leukemia, Hairy Cell 1Leukemia 1Hepatitis 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Chemical and Drug Induced Liver Injury 1Bulbo-Spinal Atrophy, X-Linked 1Brain Neoplasms 1

Interventions

blinatumomab 9Cyclophosphamide 7Rituximab 6Lenalidomide 6Dexamethasone 5Azacitidine 5venetoclax 4fludarabine 4Cytarabine 4fludarabine phosphate 3Maintenance 3Busulfan 3tislelizumab 2thymoglobulin 2pembrolizumab 2obinutuzumab 2daratumumab 2Whole-Body Irradiation 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Melphalan 2Immunotherapy 2Imatinib Mesylate 2Drug Therapy 2Docetaxel 2Decitabine 2Clofarabine 2Cladribine 2Carboplatin 2Calcium Dobesilate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm, Residual × Adrenal Cortex Hormones × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡